Find out in 60 seconds. The TrueEval GLP-1 Compliance Tracker grades your program against the 15 compliance signals state medical boards have specifically cited in 2025-2026 enforcement actions against compounded GLP-1 telehealth operators. Free. No login. Your data stays yours.
GFE format, prescriber licensure, titration protocol, adverse-event handling
Multi-state operations, strict-state handling, rule monitoring
503A/503B compliance, medical director, chart review
No email required to see your score. Optional email gate for the downloadable PDF report.
Where the grades come from. The 15 questions and their weights are derived from publicly available state medical board disciplinary orders, state pharmacy board enforcement actions, DEA bulletins, FDA guidance, and current statutes. We track these continuously through our regulatory intelligence system and consolidate them into one place so operators don't have to read 50 state board newsletters to know where the risk is.
The role AI plays. AI helps us summarize and condense the source material into usable assessment questions. The scoring itself is deterministic — same inputs always produce the same score, and the rubric is published below in the questions you'll see. There is no AI black box deciding your grade.
What this is not. TrueEval is not a law firm or an accounting firm. This tool is informational; it is not legal, accounting, or medical advice, and it does not create an attorney-client, accountant-client, or provider-patient relationship. If your results surface material gaps, consult qualified healthcare counsel licensed in your state before making business decisions.
Every question maps to a specific deficiency state boards have cited in 2025-2026 disciplinary actions against compounded GLP-1 prescribers. This is not a "best practices" survey — it's a defendability check.
No AI black box. The 15 questions and weights are published. Same inputs → same score, every time. You can audit how we arrived at your grade.
Tell us your state. Your gap report flags which deficiencies that specific state's medical board and pharmacy board have most aggressively enforced against in the past 18 months.
Responses are private. We don't share individual data with state regulators, the FDA, or anyone else. Email is optional, only required if you want the downloadable PDF.
Yes, it's free. No catch. The tracker is free as a public resource because we want operators to know whether their program is exposed to state board action before they get a cease-and-desist letter. Your results are private to you unless you book a compliance consultation with us.
The 15 questions and weighting reflect the specific compliance signals state medical boards have cited in 2025-2026 disciplinary actions against compounded GLP-1 programs. It's a directional grade meant to surface gaps quickly, not a substitute for an attorney-led audit. A score of B or above means you're in better shape than ~60% of operators; below C means you have material gaps that boards have specifically punished.
No. Your responses are private. We do not share individual assessment data with state medical boards, the FDA, or any regulatory body. If you provide an email to receive the full PDF report, we send it directly to you.
Yes. Run the quiz, see your score and gaps on screen, and leave. Email is only required if you want the full PDF report delivered or want a TrueEval compliance specialist to walk you through your gaps.
You're not alone — programs operating without medical-director oversight, async-only GFE, or single-state prescriber networks are the norm in the compounded GLP-1 market. The good news: every gap on the report is fixable. Take the full Compliance Assessment and we'll map the top 3 to fix in your specific state.